[go: up one dir, main page]

ES2166270B1 - Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. - Google Patents

Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.

Info

Publication number
ES2166270B1
ES2166270B1 ES009901694A ES9901694A ES2166270B1 ES 2166270 B1 ES2166270 B1 ES 2166270B1 ES 009901694 A ES009901694 A ES 009901694A ES 9901694 A ES9901694 A ES 9901694A ES 2166270 B1 ES2166270 B1 ES 2166270B1
Authority
ES
Spain
Prior art keywords
sup
phenyl
substituted
unsubstituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009901694A
Other languages
English (en)
Other versions
ES2166270A1 (es
Inventor
Ferrer Jordi Gracia
Gras Joan Feixas
Soto Jose Manuel Prieto
Noverola Armando Vega
Juan Bernat Vidal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009901694A priority Critical patent/ES2166270B1/es
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to CNB008130760A priority patent/CN1198825C/zh
Priority to DK00949400T priority patent/DK1198464T3/da
Priority to ES00949400T priority patent/ES2208378T3/es
Priority to NZ516780A priority patent/NZ516780A/en
Priority to SK135-2002A priority patent/SK1352002A3/sk
Priority to CZ2002311A priority patent/CZ2002311A3/cs
Priority to SI200030276T priority patent/SI1198464T1/xx
Priority to RU2002104935/04A priority patent/RU2258705C2/ru
Priority to PL00353827A priority patent/PL353827A1/xx
Priority to BR0012764-7A priority patent/BR0012764A/pt
Priority to TR2002/00785T priority patent/TR200200785T2/xx
Priority to HK02103667.4A priority patent/HK1044332B/en
Priority to IL14777000A priority patent/IL147770A0/xx
Priority to HU0202103A priority patent/HUP0202103A3/hu
Priority to PCT/EP2000/007062 priority patent/WO2001007441A1/en
Priority to JP2001512525A priority patent/JP2003505461A/ja
Priority to EEP200200046A priority patent/EE200200046A/xx
Priority to UA2002010660A priority patent/UA73513C2/uk
Priority to PT00949400T priority patent/PT1198464E/pt
Priority to PE2000000742A priority patent/PE20010401A1/es
Priority to AT00949400T priority patent/ATE251625T1/de
Priority to AU62772/00A priority patent/AU777571B2/en
Priority to CA002380181A priority patent/CA2380181A1/en
Priority to KR1020027001155A priority patent/KR20020022786A/ko
Priority to EP00949400A priority patent/EP1198464B1/en
Priority to DE60005838T priority patent/DE60005838T2/de
Priority to MYPI20003424A priority patent/MY129590A/en
Priority to TW089114927A priority patent/TW568912B/zh
Priority to CO00056184A priority patent/CO5190717A1/es
Priority to ARP000103896A priority patent/AR024969A1/es
Priority to UY26258A priority patent/UY26258A1/es
Priority to ZA200200561A priority patent/ZA200200561B/en
Priority to BG06346A priority patent/BG106346A/xx
Priority to US10/057,847 priority patent/US7034016B2/en
Priority to NO20020391A priority patent/NO20020391L/no
Publication of ES2166270A1 publication Critical patent/ES2166270A1/es
Application granted granted Critical
Publication of ES2166270B1 publication Critical patent/ES2166270B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de 8-fenil-6,9-dihidro[1,2,4]triazolo[3,4-i]purin-5-ona de fórmula (I): **FIGURA** en donde: R{sup,1}, R{sup,2} y R{sup,3} cada uno independientemente representan: hidrógeno; un grupo orgánico lineal ramificado o cíclico sustituido o no sustituido, cicloalifático o aromático, homocíclico o heterocíclico, R{sup,4} y R{sup,5} juntos con el átomo de nitrógeno al cual están unidos forman un anillo de 3 a 7 miembros que comprende un total de 1 a 4 heteroátomos seleccionados entre nitrógeno, oxígeno y azufre, cuyo anillo puede estar no sustituido o sustituido; o R{sup,4} y R{sup,5} representan independientemente un átomo de hidrógeno o un grupo alquilo el cual puede estar no sustituido o sustituido, o R{sup,4} representa hidrógeno o un grupo alquilo y R{sup,5} representa un grupo de fórmula -(CH{sub,2}){sub,n}-R{sup,7} en donde n es un número del 0 al 4 y R{sup,7} representa: un grupo orgánico; o R{sup,4} y R{sup,5} representan grupos hidroxilo, alcoxilo, hidroxialcoxilo, fenilo, alcoxicarbonilo, amino, mono- o di- alquilamino o hidroxi carbonilo; o una sal farmacéuticamente aceptable de los mismos; procedimientos para su preparación, composiciones farmacéuticas que los contengan y su uso como inhibidores de la PDE 5.
ES009901694A 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. Expired - Fee Related ES2166270B1 (es)

Priority Applications (36)

Application Number Priority Date Filing Date Title
ES009901694A ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
PT00949400T PT1198464E (pt) 1999-07-27 2000-07-24 Derivados 8-fenil-6,9-di-hidro-¬1,2,4|triazolo¬3,4-i|puri-5-ona
ES00949400T ES2208378T3 (es) 1999-07-27 2000-07-24 Derivados de 8-fenil-6,9-dihidro-1,2,4)triazolo(3,4-i)purin-5-onas.
NZ516780A NZ516780A (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives
SK135-2002A SK1352002A3 (en) 1999-07-27 2000-07-24 8-Phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives
CZ2002311A CZ2002311A3 (cs) 1999-07-27 2000-07-24 8-Fenyl-6,9-dihydro/1,2.4/triazolo/3,4-i/purin-5-onové deriváty
SI200030276T SI1198464T1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-(1,2,4)TRIAZOLO(3,4-i)PURIN-5-ONE DERIVATIVES
RU2002104935/04A RU2258705C2 (ru) 1999-07-27 2000-07-24 ПРОИЗВОДНЫЕ 8-ФЕНИЛ-6,9-ДИГИДРО[1,2,4]-ТРИАЗОЛО[3,4-i]ПУРИН-5-ОНА, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
PL00353827A PL353827A1 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i
BR0012764-7A BR0012764A (pt) 1999-07-27 2000-07-24 Composto, processo para preparar um composto, composição farmacêutica, uso de um composto e método de tratar um paciente humano ou animal
TR2002/00785T TR200200785T2 (tr) 1999-07-27 2000-07-24 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
HK02103667.4A HK1044332B (en) 1999-07-27 2000-07-24 8-Phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-I]purin-5-one derivative
IL14777000A IL147770A0 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-[1,2,4] triazolo[3,4-i] purin-5-one derivatives
HU0202103A HUP0202103A3 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives, their use, pharmaceutical compositions containing them, process for the preparation of the compounds and intermediates
DK00949400T DK1198464T3 (da) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro[1,2,4]triazolo[3,4-i]purin-5-onderivater
JP2001512525A JP2003505461A (ja) 1999-07-27 2000-07-24 ８−フェニル−６，９−ジヒドロ−［１，２，４］トリアゾロ［３，４−ｉ］プリン−５−オン誘導体
EEP200200046A EE200200046A (et) 1999-07-27 2000-07-24 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
UA2002010660A UA73513C2 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9 ûDIHYDRO- [1,2,4] TRIAZOLO [3,4-I] PURIN û5-ON DERIVATIVES, A METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON
CNB008130760A CN1198825C (zh) 1999-07-27 2000-07-24 8－苯基－6,9－二氢－[1,2,4]三唑并[3,4－i]嘌呤－5－酮衍生物
PCT/EP2000/007062 WO2001007441A1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES
DE60005838T DE60005838T2 (de) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ON DERIVATE
AU62772/00A AU777571B2 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)purin-5-one derivatives
CA002380181A CA2380181A1 (en) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-¬1,2,4|triazolo¬3,4-i|purin-5-one derivatives
KR1020027001155A KR20020022786A (ko) 1999-07-27 2000-07-24 8-페닐-6,9-디히드로-[1,2,4]트리아졸로[3,4-ｉ]푸린-5-온유도체
EP00949400A EP1198464B1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES
AT00949400T ATE251625T1 (de) 1999-07-27 2000-07-24 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)puri - 5-on derivate
PE2000000742A PE20010401A1 (es) 1999-07-27 2000-07-24 DERIVADOS DE 8-FENIL-6,9-DIHIDRO-[1,2,4] TRIAZOL [3,4-i] PURIN-5-ONA COMO INHIBIDORES DE FOSFODIESTERASA ESPECIFICA DE GMP CICLICO
MYPI20003424A MY129590A (en) 1999-07-27 2000-07-26 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES
TW089114927A TW568912B (en) 1999-07-27 2000-07-26 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives
CO00056184A CO5190717A1 (es) 1999-07-27 2000-07-26 Derivados de 8-fenil-6,9 dihidro-[1,2,4]triazol[3,4,i] purin-5-ona
UY26258A UY26258A1 (es) 1999-07-27 2000-07-27 Derivados de 8-fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-ona.
ARP000103896A AR024969A1 (es) 1999-07-27 2000-07-27 Derivados de 8-fenil-6,9-dihidro-[1,2,4]triazol[3,4-i]purin-5-ona
ZA200200561A ZA200200561B (en) 1999-07-27 2002-01-22 8-phenyl-6,9-dihydro[1,2,4]triazolo[3,4-i]purin-5-one derivatives.
BG06346A BG106346A (en) 1999-07-27 2002-01-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO-[3,4-i]PURIN-5-ONE DERIVATIVES
NO20020391A NO20020391L (no) 1999-07-27 2002-01-25 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater
US10/057,847 US7034016B2 (en) 1999-07-27 2002-01-25 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901694A ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.

Publications (2)

Publication Number Publication Date
ES2166270A1 ES2166270A1 (es) 2002-04-01
ES2166270B1 true ES2166270B1 (es) 2003-04-01

Family

ID=8309393

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009901694A Expired - Fee Related ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
ES00949400T Expired - Lifetime ES2208378T3 (es) 1999-07-27 2000-07-24 Derivados de 8-fenil-6,9-dihidro-1,2,4)triazolo(3,4-i)purin-5-onas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00949400T Expired - Lifetime ES2208378T3 (es) 1999-07-27 2000-07-24 Derivados de 8-fenil-6,9-dihidro-1,2,4)triazolo(3,4-i)purin-5-onas.

Country Status (34)

Country Link
US (1) US7034016B2 (es)
EP (1) EP1198464B1 (es)
JP (1) JP2003505461A (es)
KR (1) KR20020022786A (es)
CN (1) CN1198825C (es)
AR (1) AR024969A1 (es)
AT (1) ATE251625T1 (es)
AU (1) AU777571B2 (es)
BG (1) BG106346A (es)
BR (1) BR0012764A (es)
CA (1) CA2380181A1 (es)
CO (1) CO5190717A1 (es)
CZ (1) CZ2002311A3 (es)
DE (1) DE60005838T2 (es)
DK (1) DK1198464T3 (es)
EE (1) EE200200046A (es)
ES (2) ES2166270B1 (es)
HK (1) HK1044332B (es)
HU (1) HUP0202103A3 (es)
IL (1) IL147770A0 (es)
MY (1) MY129590A (es)
NO (1) NO20020391L (es)
NZ (1) NZ516780A (es)
PE (1) PE20010401A1 (es)
PL (1) PL353827A1 (es)
PT (1) PT1198464E (es)
RU (1) RU2258705C2 (es)
SK (1) SK1352002A3 (es)
TR (1) TR200200785T2 (es)
TW (1) TW568912B (es)
UA (1) UA73513C2 (es)
UY (1) UY26258A1 (es)
WO (1) WO2001007441A1 (es)
ZA (1) ZA200200561B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE0300917D0 (sv) 2003-03-31 2003-03-31 St Jude Medical Multi-chamber pacing system
CA2529307C (en) 2003-06-13 2013-12-24 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1812006A2 (en) * 2004-11-18 2007-08-01 Schering Corporation Methods of using pde v inhibitors for the treatment of congestive heart failure
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
WO2019135259A1 (en) 2018-01-04 2019-07-11 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
EP3845535B1 (en) * 2018-08-30 2024-06-26 Tera Stone Co., Ltd Hydrazinopurine compound and triazolopurine compound for inhibiting xanthine oxidase
CN112225761B (zh) * 2020-12-16 2021-03-12 南京颐媛生物医学研究院有限公司 一种嘧啶并三氮唑及其合成方法
EP4305033B1 (en) * 2021-03-09 2025-05-07 Basf Se Tricyclic pesticidal compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DK0417790T3 (da) * 1989-09-14 1997-04-07 Kyowa Hakko Kogyo Kk S-triazolo(3,4-i)purin-derivater
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
US5990118A (en) * 1995-02-21 1999-11-23 Yamasa Corporation Purine compounds and xanthine oxidase inhibitors
PL336586A1 (en) * 1997-04-25 2000-07-03 Pfizer Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
WO2002012246A1 (en) * 2000-08-09 2002-02-14 Almirall Prodesfarma S.A. Pyrrolotriazolopyrimidinone derivatives

Also Published As

Publication number Publication date
AU6277200A (en) 2001-02-13
HK1044332B (en) 2004-10-15
UY26258A1 (es) 2000-12-29
HK1044332A1 (en) 2002-10-18
RU2258705C2 (ru) 2005-08-20
CN1198825C (zh) 2005-04-27
NO20020391D0 (no) 2002-01-25
CA2380181A1 (en) 2001-02-01
IL147770A0 (en) 2002-08-14
ZA200200561B (en) 2003-06-25
CO5190717A1 (es) 2002-08-29
PE20010401A1 (es) 2001-04-16
MY129590A (en) 2007-04-30
JP2003505461A (ja) 2003-02-12
DK1198464T3 (da) 2004-02-16
HUP0202103A2 (en) 2002-10-28
CZ2002311A3 (cs) 2003-01-15
PL353827A1 (en) 2003-12-01
TR200200785T2 (tr) 2002-09-23
HUP0202103A3 (en) 2004-12-28
DE60005838D1 (de) 2003-11-13
TW568912B (en) 2004-01-01
CN1374962A (zh) 2002-10-16
KR20020022786A (ko) 2002-03-27
EP1198464B1 (en) 2003-10-08
ES2208378T3 (es) 2004-06-16
ES2166270A1 (es) 2002-04-01
EE200200046A (et) 2003-04-15
BG106346A (en) 2002-09-30
US7034016B2 (en) 2006-04-25
UA73513C2 (en) 2005-08-15
BR0012764A (pt) 2002-07-02
WO2001007441A1 (en) 2001-02-01
SK1352002A3 (en) 2003-04-01
EP1198464A1 (en) 2002-04-24
AR024969A1 (es) 2002-10-30
NO20020391L (no) 2002-03-25
US20030060627A1 (en) 2003-03-27
DE60005838T2 (de) 2004-08-19
ATE251625T1 (de) 2003-10-15
PT1198464E (pt) 2004-02-27
NZ516780A (en) 2004-01-30
AU777571B2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
ES2166270B1 (es) Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
AR070193A1 (es) Terapia combinada que comprende inhibidores de sglt e inhibidores de dpp4, composicion farmaceutica y uso
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
RU94031155A (ru) Амидин - производные, способ их получения, их использование в качестве ингибиторов no - синтазы, фармсостав, способ лечения
DK419086A (da) Heterocykliske substituerede indoler, mellemprodukter, fremgangsmaader til fremstilling heraf og laegemidler
AR034253A1 (es) Compuestos activadores de glucoquinasa que contienen hidantoina sustituida, un procedimiento para su preparacion, composiciones farmaceuticas, procedimientos para su preparacion, empleo de los mismos para la preparacion de medicamentos
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
AR030279A1 (es) Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos.
ES2162466T3 (es) Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.
ES2174579T3 (es) Nuevos derivados benzotiofenicos, benzofuranicos e indolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DOP2006000063A (es) Derivados de ciclopropanocarboxamida
AR043959A1 (es) Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos
AR065131A1 (es) Derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR039927A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen
ECSP066542A (es) Derivados de disulfuro, sulfuro, sulfóxido, y sulfota de azúcares cíclicos y sus usos
AR012436A1 (es) Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion.
AR019256A1 (es) Utilizacion de derivados tetraciclo[6-6-2-0(2.27).0(9.14)] hexadeca-2(7), 3, 5, 9(14), 10,12-hexaeno, para la preparacion de preparados farmaceuticos conaccion inhibitoria de la fosfolipasa, los referidos derivados y preparado farmaceutico que contiene por lo menos a uno de dichos derivados
AR018619A1 (es) Derivados de 8-fenilxantina utiles como inhibidores de fosfoestearasa gmp ciclica (pdes), preparacion, composiciones farmaceuticas formuladas con dichosderivados y uso de dichos derivados para la fabricacion de medicamentos

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020401

Kind code of ref document: A1

Effective date: 20020401

FG2A Definitive protection

Ref document number: 2166270B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100528